Phase 3 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with multiple myeloma (a type of blood cancer) based on standard international diagnostic criteria, with measurable signs of the disease at the time of diagnosis.
- People aged 18 or older.
- People who have completed 12 cycles (or up to 13 cycles) of a treatment combination called Dara-Rd (daratumumab, lenalidomide, and dexamethasone), and are able to continue on that same treatment.
- People whose lenalidomide dose may have been reduced, but not below 5 mg, and who may have had their dexamethasone dose reduced or stopped — this is still acceptable.
- People whose disease has responded at least partially to 12 cycles of Dara-Rd treatment, with no signs that the disease is starting to return or worsen based on blood or lab markers.
- People with blood counts at or above certain minimum levels — specifically, a white blood cell type count of at least 1.0×10⁹/L and a platelet count of at least 75×10⁹/L (confirm with trial site if unsure what this means for your situation).
- People who are able to understand the trial and provide written agreement to participate.
Who may not be able to join:
- People whose myeloma did not produce measurable proteins in the blood or urine at the time of diagnosis (known as non-secretory myeloma).
- People whose myeloma could only be measured through a localised tumour (called a plasmacytoma) at the time of diagnosis, with no other measurable markers.
- People whose myeloma could only be measured through urine protein levels at the time of diagnosis, with no other measurable markers.
- People who have had to stop taking daratumumab, lenalidomide, or both for any reason — only stopping dexamethasone is acceptable.
- People for whom a treating doctor has determined that continuing Dara-Rd treatment is not medically possible.
- People whose personal, psychological, family, or geographical circumstances may make it difficult to follow the trial's schedule and requirements.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sonja Zweegman, Prof Dr MD, Amsterdam UMC
Phone: 0031 20 4442604
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Compare Event-Free Survival (EFS); Compare Progression Free Survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.